Current world schistosomiasis overview;Panorama atual da esquistossomíase no mundo

Revista Brasileira de Ciencias Farmaceuticas/Brazilian Journal of Pharmaceutical Sciences

Volumn 37, Issue 2, 2001, Pages 123-135

  Parise Filho, R ^a   Da Silveira, M A B ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Chemotherapy; Diagnosis; Epidemiology; Schistosomiasis; Vaccine

Indexed keywords

ANTIMALARIAL AGENT; CYCLOSPORIN; METRIFONATE; NIRIDAZOLE; OLTIPRAZ; OXAMNIQUINE; PRAZIQUANTEL;

HUMAN; INFECTION RISK; PREVALENCE; PUBLIC HEALTH; REVIEW; RISK FACTOR; SANITATION; SCHISTOSOMA; SCHISTOSOMIASIS; TROPICS;

EID: 0035156714     PISSN: 15169332     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Vaccines against human parasitic diseases: An overview
2. Detection of Schistosoma mansoni in bronchoalveolar lavage fluid: A case report
3. Schistosomiasis in India with the possiblity of its diagnosis in man
4. The global status of schistosomiasis and its control
5. Schistosomiasis in the republic of São Tome and Principe: Human studies
6. Susceptibility of chemotherapeutic agents of strains of Schistosoma mansoni isolated from treated and untreated patients
7. Schistosomiasis vaccines: Research to development
8. Protection against schistosomiasis produced by cyclosporina A
9. Chemotherapy of schistosomiasis: An update
10. Drug resistance to schistosomicides and other antihelmentics of medical significance
11. Schistosomiasis CD-ROM
12. Schistosomiasis: Forty years' war on the worm
13. Neurotoxicidade do oxamniquine no tratamento da infeção humana pelo Schistosoma mansoni
14. Chemotherapy of schistosomiasis: An update
15. Antischistosomal drugs: Past, present...and future?
16. The global status of schistosomiasis and its control
17. The successful use of antimony in bilharziosis. Administered as intravenous injections of antimonium tartaratum (tartar emetic)
18. Antischistosomal drugs: Past, present...and future?
19. Activity of oxamniquine at skin, pulmonary and sexual maturation phases, on a Schistosoma mansoni strain (R1) previously reported as resistant at the adult phase
20. Resistance to oxamniquine of Schistosoma mansoni strain isolated from patient submitted to repeated treatments
21. Study of Schistosoma mansoni isolates from patients with failure of treatment with oxamniquine
22. Quantitative diagnosis of schistosoma infections by measurement of circulating antigens in serum and urine
23. Immunodiagnosis of schistosomiasis by determination of the circulating antigens CAA and CCA, in particular in individuals with recent or light infections
24. Linhagem humana de Schistosoma mansoni resistente a esquistossomicidas
25. A vaccine for schistosomiasis: Alternative aproaches
26. The impact to the local water development programme on the abundance of the intermediate hosts of schistosomiasis in three villages of the Senegal river delta
27. Prevalence and epidemiology of S. haematobium infection in two areas of Egypt recently reclaimed from the desert
28. Drug-resistant schistosomiasis: Resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific
29. Should nutrition be considered as a supplementary measure in schistosomiasis control?
30. Fiocruz estuda vacina contra esquistossomose
31. Epidemiology of HIV and Schistosoma mansoni infections among sugar-estate residents in Ethiopia
32. Effect of insect-growth disrupting amines and amides on Schistosoma mansoni in vitro
33. The role of corticosteroids in the treatment of cerebral schistosomiasis caused by S. mansoni - Case report and discussion
34. Parasitologia médica
35. Researchers fret over neglect of 600 million patients
36. Post-transmission schistosomiasis
37. Arritmia cardíaca com uso de oxamniquine oral no tratamento de esquistossomose mansônica
38. Schistosomiasis research: The end of the beginning
39. Resistance to praziquantel: Direct evidence from Schistosoma mansoni isolated from egyptian villagers
40. Schistosomiasis
41. Studies on schistosomiasis in western Kenya: I. Evidence for immune-facilitated excretion of schistosome eggs from patients with Schistosoma mansoni and human immunodeficiency virus coinfections
42. Immunodiagnosis of schistosomiasis by determination of the circulating antigens CAA and CCA, in particular in individuals with recent or light infections
43. Dificuldades no desenvolvimento de uma vacina para esquistossomose mansoni
44. Schistosomiasis control in Brazil
45. Resinatos de agentes esquistossomicidas
46. Safety and toxicity of oxamniquine in the treatment of Schistosoma mansoni infections, with particular reference to electroencephalographic abnormalities
47. Salmonella-S. mansoni association in patients with acquired immunodeficiency syndrome
48. Schistosoma mansoni: Assessment of morbidity before and after control
49. Studies on prophylatic effect of artesunate on schistosomiasis japonica
50. Chemotherapy of schistosomiasis: An update
51. The search for a vaccine against schistosomiasis: A difficult path but an achievable
52. Treatment of schistosomiasis
53. Global estimates and epidemiology of HIV infections and AIDS
54. Análise químico-farmacêutica da oxamniquina e de suas especialidades farmacêuticas
55. Schistosomiasis of the female genital tract: Public health aspects
56. An interactive perspective of health education for the tropical disease control: The schistosomiasis case
57. Preventive effect of artemether in experimental animals infected with Schistosoma mansoni
58. Experimental studies on early treatment of schistosomal infection with artemether
59. Chemotherapy of schistosomiasis: An update
60. In vitro and in vivo studies of the effect of artemether on Schistosoma mansoni
61. Combate a esquistossomiase
62. Latencia̧ão de agentes esquistossomicidas e antimaláricos
63. Ultrasound appearance of schistosomiasis of the testis
64. Schistosomiasis in the Senegal river basin: Before and after the construction of the damas at Diama, Senegal and Mantali, Mall and future prospects
65. The crucial role of spacer groups in macromolecular prodrug design
66. Convulsions after oxamniquine
67. Immunodiagnosis of schistosomiasis by determination of the circulating antigens CAA and CCA, in particular in individuals with recent or light infections
68. Advances in schistosomiasis research
69. Failure to induce resistance of Schistosoma japonicum to praziquantel